TG Therapeutics TGTX Product — Accounts Payable And Accrued Liabilities Current
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
As of June 30, 2026, gross-to-net accruals of approximately $29.2 million and $69.3 million are included on the condensed consolidated balance sheets within accounts receivable, net, and accounts payable and accrued expenses, respectively. As of June 30, 2025, gross-to-net accruals of approximately $16.1 million and $33.3 million are included on the condensed consolidated balance sheets within accounts receivable, net, and accounts payable and accrued expenses, respectively.
Document
FAQ
- What is TG Therapeutics's product — accounts payable and accrued liabilities current?
- TG Therapeutics (TGTX) reported product — accounts payable and accrued liabilities current of $69.3M in Q2 2026.
- What does product — accounts payable and accrued liabilities current mean?
- This represents the short-term obligations the company owes to suppliers and service providers specifically related to its product operations. It encompasses trade payables and accrued expenses such as distribution costs or manufacturing fees. This metric provides insight into the company's short-term operational liabilities and cash management strategy.
Ask your AI about TG Therapeutics's product — accounts payable and accrued liabilities current.
Connect your AI assistant and compare it to peers, right in your chat.
